Enanta Pharmaceuticals
ENTA • NASDAQ
Enanta Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Jay R. Luly, with a market cap of $353.5M.
CEOJay R. Luly
Next Earnings
Upcoming earnings announcement for Enanta Pharmaceuticals
Date
Monday, May 11, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q2 2026
EPS Estimate
-$0.49
Revenue Estimate
$17.1M
Earnings History
Past 12 earnings reports for Enanta Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 9, 2026 | Q1 2026 | -$0.42Est: -$0.74 | +43.2% | $18.6MEst: $15.4M | +20.7% | — |
| Nov 17, 2025 | Q4 2025 | -$0.87Est: -$1.06 | +17.9% | $15.1MEst: $15.8M | -4.4% |  10-K |
| Aug 11, 2025 | Q3 2025 | -$0.85Est: -$1.03 | +17.5% | $18.3MEst: $15.4M | +18.8% | 10-Q |
| May 12, 2025 | Q2 2025 | -$1.06Est: -$1.46 | +27.4% | $14.9MEst: $15.9M | -6.4% | 10-Q |
| Feb 10, 2025 | Q1 2025 | -$1.05Est: -$1.35 | +22.2% | $17.0MEst: $17.3M | -1.7% | 10-Q |
| Nov 25, 2024 | Q4 2024 | -$1.36Est: -$1.41 | +3.5% | $14.6MEst: $16.1M | -9.1% | 10-K |
| Aug 5, 2024 | Q3 2024 | -$1.07Est: -$1.45 | +26.2% | $18.0MEst: $17.2M | +4.6% | 10-Q |
| May 6, 2024 | Q2 2024 | -$1.47Est: -$1.33 | -10.5% | $17.1MEst: $16.5M | +3.2% | 10-Q |
| Feb 7, 2024 | Q1 2024 | -$1.58Est: -$1.19 | -32.8% | $18.0MEst: $21.3M | -15.4% | 10-Q |
| Nov 20, 2023 | Q4 2023 | -$1.33Est: -$2.00 | +33.5% | $18.9MEst: $17.5M | +8.2% | — |
| Aug 7, 2023 | Q3 2023 | -$1.86Est: -$2.33 | +20.2% | $18.9MEst: $18.1M | +4.6% | 10-Q |
| May 8, 2023 | Q2 2023 | -$1.79Est: -$1.98 | +9.6% | $17.8MEst: $19.2M | -7.2% | 10-Q |